Evidence map›Paper›PMID 30662615›Full record

ArticleAmerican journal of translational research2018

Ribonucleotide reductase subunit M2B deficiency leads to mitochondrial permeability transition pore opening and is associated with aggressive clinicopathologic manifestations of breast cancer.

Lijun Xue, Xiyong Liu, Qinchuan Wang, Charlie Q Liu, Yunru Chen, Wei Jia, Ronhong Hsie, Yifan Chen, Frank Luh, Shu Zheng and 1 more

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Lijun XueDepartment of Pathology, Loma Linda University Medical Center Loma Linda, CA 92354, USA.
Xiyong LiuSino-American Cancer Foundation, California Cancer Institute Temple, CA 91780, USA.
Qinchuan WangDepartment of Molecular Pharmacology, Beckman Research Institute, City of Hope Comprehensive Cancer Center Duarte, CA 91010, USA.
Charlie Q LiuDepartment of Molecular Pharmacology, Beckman Research Institute, City of Hope Comprehensive Cancer Center Duarte, CA 91010, USA.
Yunru ChenDepartment of Molecular Pharmacology, Beckman Research Institute, City of Hope Comprehensive Cancer Center Duarte, CA 91010, USA.
Wei JiaCancer Epidemiology Program, University of Hawaii Cancer Center Honolulu, HI 96813, USA.
Ronhong HsieTMU Research Center of Cancer Translational Medicine, Taipei Medical University Taipei, Taiwan, ROC.
Yifan ChenPhD Program of Cancer Biology and Drug Discovery, Taipei Medical University Taipei, Taiwan, ROC.
Frank LuhSino-American Cancer Foundation, California Cancer Institute Temple, CA 91780, USA.
Shu ZhengCancer Institute, Zhejiang University Hangzhou 310009, Zhejiang, China.
Yun YenSino-American Cancer Foundation, California Cancer Institute Temple, CA 91780, USA.
Taipei Medical University · TWCity Of Hope National Medical Center · USZhejiang University · CNLoma Linda University Health Care · USUniversity of Hawaiʻi at Mānoa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ribonucleotide reductase small subunit M2B (RRM2B) plays an essential role in maintaining mitochondrial homeostasis. Mitochondrial permeability transition pore (MPTP) is a key regulator of mitochondrial homeostasis. MPTP contributes to cell death and is crucial in cancer progression. RRM2B's relation to MPTP is not well known, and the role of RRM2B in cancer progression is controversial. Here, our aim was to study the role of RRM2B in regulating MPTP and the association between RRM2B and clinicopathological manifestations in breast cancer. Analysis of

Indexed as

aggressive manifestations of breast cancercyclophilin Dmitochondrial permeability transition poreRibonucleotide reductase small subunit M2Bspermine

Identifiers

PMID30662615
PMCPMC6291710
OpenAlexW2939475328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.